Why haven't biologists cured cancer?
Cancer’s stubborn resistance to a definitive “cure” is framed as a consequence of its complexity: it is not a single disease but a vast family of evolving, patient-specific conditions rooted in our own cells. Commenters highlight how biological intricacy, slow experimental cycles, ethical and regulatory limits, fragmented and proprietary data, and economic incentives all constrain progress, even as targeted therapies and immunotherapies deliver major advances for some cancers. Many argue that future breakthroughs are more likely to come from earlier detection, immune-based and systems-level approaches, and much greater investment in open, large-scale biological research rather than a single miracle drug.
Cancer Complexity and Diversity
- Repeated emphasis that there is no single “cure for cancer”; cancers are a large, heterogeneous family of diseases.
- Cancer is framed as rogue self-cells, often a hallmark of aging, exploiting normal body systems and evading immunity.
- Metastasis, genetic instability, and enormous combinatorial space (trillions of cells, billions of base pairs) make prediction and control inherently hard.
- Some cancers are effectively curable; others remain highly resistant, with each patient’s tumor genetically and biologically unique.
Limits of “Find and Destroy the Rogue Cells”
- One camp suggests cancer is solvable by tech that identifies and destroys abnormal cells, largely “ignoring biology.”
- Clinicians and researchers push back: cancer cells often resemble normal cells; the immune system already does imperfect anomaly detection; scale and uncertainty are massive.
- Analogies to debugging an undocumented, non-orthogonal system highlight that interventions can cause severe unintended consequences.
Detection, Diagnostics, and Early Screening
- Strong interest in early detection (e.g., cfDNA, fragmentome, multi-cancer blood tests).
- Others note current assays (e.g., PSA) have poor specificity and that systematically applying sophisticated diagnostics is hard and expensive.
- Some argue early detection could dramatically reduce mortality; others warn that scalability and test quality are major bottlenecks.
Therapies, Approaches, and Reductionism
- Targeted drugs and immunotherapies (e.g., PD-1 inhibitors) cited as genuine breakthroughs, but usually narrow and not universal.
- Debate over whether the dominant gene/protein-centric paradigm is too reductionist; alternative frameworks (e.g., bioelectric/morphogenesis views) are proposed and contested.
- Comparisons with physics underscore how messy, slow, and tool-limited biological experiments are.
Institutions, Incentives, and Culture
- Complaints about regulatory conservatism, especially around clinical trials for terminal patients.
- Concerns about funding scarcity, long timelines, proprietary datasets/instruments, and high “friction” for tests.
- Some blame profit motives and suggest cures are disfavored or buried; others question the plausibility of such schemes.
- Criticism of academic cancer research culture: senior scientists chasing grants and prestige while underpaid juniors do most lab work.
- Broader culture seen as underinvesting in biology and tolerating unhealthy lifestyles, which may counter medical gains.